Abstract library

168 results for "gastrointestinal motility".
#118 Gastrointestinal motility in patients with neuroendocrine tumors
Introduction: Diarrhea is the most common symptom in patients with intestinal neuroendocrine tumors (NET). Somatostatin analogues reduce stool frequency and may increase gastrointestinal transit time (GITT). Motility tracking system® MTS-1 (MTS) (Motilis, Switzerland) is a novel, safe, almost non-invasive and easy-to-perform method for description of gastrointestinal motility.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Tine Gregersen
#349 Gastrointestinal Stromal Tumor (GIST) Of The Esophagus In A Patient With MEN-1 And-Related Pancreatic Gastrinoma
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Conference:
Category: Basic
Presenting Author: Dr Roberta E Rossi
#426 An Esophageal Gastrointestinal Stromal Tumor (GIST) in a Patient with MEN-1 Related Pancreatic Gastrinoma
Introduction: Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Roberta E Rossi
#134 Gastrointestinal neuroendocrine tumors: tumor characteristics and long-term clinical outcome in the German NET registry
Introduction: Prognosis of neuroendocrine tumors (NETs) has been difficult to predict due to heterogenous tumor biology, various classification systems, and lack of reliable and recent data due to the rarity of these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Ulrich-Frank Pape
Authors: Maasberg S, König A, Rinke A, Anlauf M, ...
#1304 Analysis of 18FDG-PET/CT in Patients with Gastrointestinal Neuroendocrine Neoplasm
Introduction: Gastrointestinal neuroendocrine neoplasm (Gi-NEN) comprised a wide and heterogeneous group of neoplasms. Diagnosis could often be challenging due to their rarity. 18FDG-PET/CT had a high accuracy for poorly differentiated NENs.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jiangyuan Yu
Authors: Yu J, Yang Z, Fan Y, Lu M, ...
#1429 Evaluate the Accuracy of Pathological Diagnosis on Biopsy Specimens from Gastrointestinal Neuroendocrine Tumors
Introduction: Gastrointestinal neuroendocrine neoplasms (GI-NENs) is a highly heterogeneous tumor. The accuracy of pathological diagnosis on the biopsy is crucial for GI-NENs but rarely investigated
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Doctor Li Sun
Authors: Sun L, Li S, Li J, Lu M, ...
#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...
#770 The Axon Guidance Molecules Slit2 and Robo Control Motility and Growth of Pancreatic Neuroendocrine Tumor Cells
Introduction: Dense vascularization and high frequency of metastasis in pancreatic neuroendocrine tumors (pNET) suggest a central role for the interaction of tumor cells and vessels. Slit2 and its receptors Robo1 and Robo4 act as guidance cues in neurogenesis, angiogenesis and epithelial morphogenesis, and hence represent attractive candidate regulators at the tumor cell/stroma interface.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Christian Fischer
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#1826 An Intrapatient Comparison of 18FDG And 68Ga-DOTA-TATE PET/CT Imaging in Patients with Gastrointestinal Neuroendocrine Neoplasm
Introduction: 18FDG-PET/CT was the most widely used functional imaging for cancer, while 68Ga-DOTA-TATE PET/CT could evaluate the SSTR expression of NEN.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jiangyuan Yu
Authors: Yu J, lI J, Zhang P, Lu M, ...